Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-520 in HBeAg negative chronic hepatitis B
NCT02604199Phase 2Terminated
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Sep 2015
- Primary completion
- Jan 2017
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
A Phase 2 trial of ARC-520 in Chronic Hepatitis B (CHB), sponsored by Arrowhead Pharmaceuticals. Started Sep 2015; status: terminated.
02
Drugs
ARC-520
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02604199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02604199.